Extending patient survival with next-generation treatment combinations.

Development Pipeline

We are advancing a pipeline of innovative immuno-oncology programs.

Coherus is developing a diversified pipeline of immuno-oncology therapeutics that can be part of next-generation treatment combinations to extend survival for patients with cancer across difficult-to-treat tumor types. Our pipeline programs have distinct targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment with the goal of delivering powerful anti-tumor activity and, ultimately, transforming outcomes for patients. Our pipeline includes a range of novel preclinical and clinical-stage immuno-oncology programs currently in development.

Coherus-led Immuno-oncology Programs
Program
Target
Indication
Stage
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
  • Approved
PD-1
Nasopharyngeal Carcinoma

(IL combo with chemo)
Approved
Nasopharyngeal Carcinoma

(2L/3L monotherapy)
Approved
Approved
Approved
IL-27
Hepatocellular Carcinoma
Phase 2
Non-Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2
CCR8
Solid Tumors

(including head & neck cancer)
Phase 1
Phase 1
ILT4
Solid Tumors
(combined with toripalimab)
Pre Clin.
Pre Clin.

* Coherus owns the rights to LOQTORZI in the United States and Canada.

Licensed Immuno-oncology Programs
Program
Target
Indication
Stage
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
  • Approved
NZV930^
CD73
Solid Tumors
Phase 1
Phase 1
GSK4381562^^
PVRIG
Solid Tumors
Phase 1
Phase 1

^ Coherus has licensed worldwide rights to Novartis.
^^ Coherus has licensed worldwide rights to GSK.

Learn more about toripalimab, our next generation anti-PD-1 monoclonal antibody.